SYDNEY, Australia, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced results of RECCE ® ...
Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® ...
Over the last year, a good number of insiders have significantly increased their holdings in Recce Pharmaceuticals ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
To get a sense of who is truly in control of Recce Pharmaceuticals Ltd (ASX:RCE), it is important to understand the ownership structure of the business. We can see that retail investors own the lion's ...
This new patent strengthens Recce’s intellectual property footprint across Asia, supporting its strategy to access high-growth ASEAN markets. The patent claims cover Recce Pharmaceuticals (ASX:RCE) ...
Recce Pharmaceuticals Ltd. (AU:RCE) has released an update. Recce Pharmaceuticals Ltd has completed a pivotal phase of its Phase I/II clinical trial by successfully dosing 6 subjects with a high-dose, ...
Phase 1/2 trial of RECCE ® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical Research Study will assess the ...
Recce Pharmaceuticals Ltd. (AU:RCE) has released an update. Recce Pharmaceuticals is set to begin a pivotal Phase 3 clinical trial in Indonesia for their RECCE 327 topical gel, targeting diabetic foot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results